Merck KGaA Buys Sigma-Aldrich To Boost Lab Business, Expand Footprint
This article was originally published in The Pink Sheet Daily
Executive Summary
By buying U.S.-based Sigma-Aldrich, the German conglomerate hopes to bolster its Millipore lab business, by giving the biopharma technology, tools and service provider added depth and global reach.
You may also be interested in...
European Notebook: Rasi To Review EMA Plans; Spain’s Drug Spend Held Flat By Industry; Insurers Merge In Germany
Re-appointed EMA Executive Director Guido Rasi will outline his plans for the agency in early December; pact in Spain calls for the pharmaceutical industry to reimburse government for spending increases above GDP growth.
Merck KGaA Rebif Faces Irreversible Decline; Avelumab Update Seen Soon
Sales of the German multinational’s best-selling MS product sharply declined in the second quarter, but higher investment is likely to boost its research pipeline of early- and late-stage products.
Merck KGAA Rebuilds Its R&D Portfolio, Re-Aligns Into Three Businesses
The diversified German company eschews the tightening of focus seen in other European pharmaceutical companies, but does subdivide its business into three units: health care, life sciences and performance materials.